June 10, 2024 11:16 AM EDT
R&D

Skye's stock sinks fol­low­ing eye dis­ease fail­ure as com­pa­ny shifts fo­cus to obe­si­ty

Katherine Lewin

News Reporter

Skye Bio­science is aban­don­ing its en­tire eye dis­ease pipeline fol­low­ing a Phase 2a tri­al fail­ure, and it’s piv­ot­ing to one of the hottest cat­e­gories in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Sam­sung Bio pulls in $1.06B man­u­fac­tur­ing deal with un­named US phar­ma com­pa­ny

Carte­sian clears an au­toim­mune CAR-T tri­al, starts an­oth­er Phase 2 and rais­es $130M

Four key weight loss read­outs to watch at #EASD24

Cas­sa­va says two se­nior em­ploy­ees in­clud­ed in fed­er­al probes

Cor­rect­ed: Boehringer In­gel­heim, Gubra put a sec­ond can­di­date in­to the obe­si­ty race

A service from the Financial Times